Immune‑maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity‑modulated radiation

Shibamoto,Yuta; Okamoto,Masato; Kobayashi,Masanori; Ayakawa,Shiho; Iwata,Hiromitsu; Sugie,Chikao; Mitsuishi,Yoko; Takahashi,Hidenori

doi:10.3892/mco.2013.108

Immune‑maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity‑modulated radiation

Authors:
- Yuta Shibamoto
- Masato Okamoto
- Masanori Kobayashi
- Shiho Ayakawa
- Hiromitsu Iwata
- Chikao Sugie
- Yoko Mitsuishi
- Hidenori Takahashi
View Affiliations

Affiliations: Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Aichi 467‑8601, Japan, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo 160‑858, Japan, Seren Clinic Nagoya, Aichi 460‑0008, Japan, Department of Radiology, Nagoya Daini Red Cross Hospital, Aichi 466‑8650, Japan, Clinic Saint Louis, Kyoto 607‑8011, Japan, Seren Clinic Tokyo, Tokyo 108‑0071, Japan
Published online on: April 26, 2013 https://doi.org/10.3892/mco.2013.108
Pages: 649-654

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A dendritic cell (DC)‑based vaccine was combined with intensity‑modulated radiotherapy (IMRT) or other conformal radiotherapy (RT), assuming minimal immunosuppression by such RT modalities. In this study, the outcomes in the first 40 patients are presented. The patients had recurrent, metastatic or locally advanced tumors. Nine had previously undergone full‑course RT. Peripheral blood mononuclear cells obtained by leukapheresis were cultured with granulocyte‑macrophage colony‑stimulating factor, interleukin‑4, OK‑432 and prostaglandin E2 to generate DCs, which were pulsed with autologous tumor lysates or tumor‑specific peptides, such as WT1. IMRT using tomotherapy, stereotactic irradiation or 3‑dimensional conformal RT (3DCRT) was initially administered. The standard dose was 30 and 60 Gy in patients with and without previous RT, respectively. Every other week thereafter, up to a total of 7 times, DC vaccines were injected directly into the tumor (n=15) or administered intradermally when DCs were pulsed with tumor lysates or peptides. The tumor response was evaluated according to the response evaluation criteria in solid tumors (RECIST). RT and DC vaccines were well tolerated and there were no major complications. Three patients were not able to complete the planned DC therapy due to disease progression. For the 31 patients receiving full‑dose RT, the response rate was 61% and for the 9 patients who had previously received RT, the response rate was 55%. In 9 patients, the tumor response outside the RT target volume was evaluable: 22% had a partial response (PR), 33% had stable disease (SD) and 44% had progressive disease (PD). In conclusion, a combination of IMRT (or 3DCRT) and DC vaccine is feasible and requires further investigation.

View Figures

View References

1.	Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991. View Article : Google Scholar : PubMed/NCBI
2.	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar
3.	Fong L and Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol. 18:245–273. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Banchereau J, Briere F, Caux C, et al: Immunobiology of dendritic cells. Annu Rev Immunol. 18:767–811. 2000. View Article : Google Scholar
5.	Higano CS, Schellhammer PF, Small EJ, et al: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 115:3670–3679. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Gliboa E: DC-based cancer vaccines. J Clin Invest. 117:1195–1203. 2007. View Article : Google Scholar
7.	Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P and Nenicioni A: Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev. 60:173–183. 2008. View Article : Google Scholar
8.	Oshita C, Takikawa M, Kume A, et al: Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial. Oncol Rep. 28:1131–1138. 2012.PubMed/NCBI
9.	Takeshima T, Chamoto K, Wakita D, et al: Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 70:2697–2706. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Ghiringhelli F, Menard C, Puig PE, et al: Metronomic cyclophosphamide regimen selectively depletes CD4⁺CD25⁺regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 56:641–668. 2007.PubMed/NCBI
11.	Ko HJ, Kim YJ, Kim YS, et al: A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67:7477–7486. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Okamoto M, Kasetani H, Kaji R, et al: cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother. 47:233–239. 1998. View Article : Google Scholar
13.	Okamoto M, Ohe G, Oshikawa T, et al: Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anticancer Drugs. 11:165–173. 2000. View Article : Google Scholar : PubMed/NCBI
14.	Ahmed SU, Okamoto M, Oshikawa T, et al: Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother. 27:432–441. 2004. View Article : Google Scholar
15.	Kimura Y, Tsukada J, Tomoda T, et al: Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 41:195–205. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Campbell AC, Hersey P, MacLennan IC, Kay HE and Pike MC: Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J. 2:385–388. 1973. View Article : Google Scholar : PubMed/NCBI
17.	Harris J, Sengar D, Stewart T and Hyslop D: The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer. 37(2 Suppl): 1058–1069. 1976. View Article : Google Scholar : PubMed/NCBI
18.	Sugiyama H: Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. Expert Rev Vaccines. 4:503–512. 2005.
19.	Mukherjee P, Ginardi AR, Madsen CS, Sterner CS, Adriance MC, Tevethia MJ and Gendler SJ: Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol. 165:3451–3460. 2000. View Article : Google Scholar
20.	Cheever MA, Allison JP, Ferris AS, et al: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 15:5323–5337. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Okamoto M, Furuichi S, Nishioka Y, et al: Expression of toll-like receptor 4 on dendritic cells is significant for anti-cancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 64:5461–5470. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Okamoto M, Oshikawa T, Tano T, et al: Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by a streptococcal agent OK-432. J Natl Cancer Inst. 95:316–326. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Okamoto M, Oshikawa T, Tano T, et al: Mechanism of anti-cancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother. 29:78–86. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Oshikawa T, Okamoto M, Tano T, et al: Anti-tumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent. J Immunother. 29:143–150. 2006.PubMed/NCBI
25.	Nakahara S, Tsunoda T, Baba T, et al: Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63:4112–4118. 2003.PubMed/NCBI
26.	Itoh T, Ueda Y, Okugawa K, et al: Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother. 52:207–214. 2003.PubMed/NCBI
27.	Sato M, Takayama T, Tanaka H, et al: Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2). Cancer Sci. 94:1091–1098. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Larbouret C, Robert B, Navarro-Teulon I, et al: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res. 13:3356–3362. 2007. View Article : Google Scholar : PubMed/NCBI
29.	Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK and Morse MA: Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with meta-static malignancies expressing CEA. Int J Cancer. 82:121–124. 1999. View Article : Google Scholar
30.	Kontani K, Taguchi O, Ozaki Y, et al: Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model. Cancer Gene Ther. 9:330–337. 2002. View Article : Google Scholar
31.	Cannon MJ, Santin AD and O’Brien TJ: Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol. 16:87–92. 2004. View Article : Google Scholar
32.	Nagayama H, Sato K, Morishita M, et al: Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res. 13:521–530. 2003. View Article : Google Scholar
33.	Sugie C, Shibamoto Y, Ayakawa S, et al: Craniospinal irradiation using helical tomotherapy: evaluation of acute toxicity and dose distribution. Technol Cancer Res Treat. 10:187–195. 2011.PubMed/NCBI
34.	Shibamoto Y, Naruse A, Fukuma H, Ayakawa S, Sugie C and Tomita N: Influence of contrast materials on dose calculation in radiotherapy planning using computed tomography for tumors at various anatomical regions: a prospective study. Radiother Oncol. 84:52–55. 2007. View Article : Google Scholar
35.	Iwata H, Shibamoto Y, Hashizume C, et al: Hypofractionated stereotactic body radiotherapy for primary and metastatic liver tumors using the Novalis image-guided system: preliminary results regarding efficacy and toxicity. Technol Cancer Res Treat. 9:619–627. 2010. View Article : Google Scholar
36.	Shibamoto Y, Hashizume C, Baba F, et al: Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study. Cancer. 118:2078–2084. 2012. View Article : Google Scholar : PubMed/NCBI
37.	Reits EA, Hodge JW, Herberts CA, et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 203:1259–1271. 2006. View Article : Google Scholar : PubMed/NCBI
38.	Suzuki Y, Mimura K, Yoshimoto Y, et al: Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 72:3967–3976. 2012. View Article : Google Scholar : PubMed/NCBI
39.	Finkelstein SE, Rodriguez F, Dunn M, et al: Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy. Immunotherapy. 4:373–382. 2012. View Article : Google Scholar
40.	Finkelstein SE, Iclozan C, Bui MM, et al: Combination of external beam radiation (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 82:924–932. 2012. View Article : Google Scholar : PubMed/NCBI
41.	Nikitina EY and Gabrilovich DI: Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer. 94:825–833. 2001. View Article : Google Scholar
42.	Gupta A, Probst HC, Vuong V, et al: Radiotherapy promotes tumor-specific effector CD8⁺T cells via dendritic cell activation. J Immunol. 189:558–566. 2012. View Article : Google Scholar : PubMed/NCBI
43.	Sharma A, Bode B, Wenger RH, et al: γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One. 6:e282172012.
44.	Postow MA, Callahan MK, Barker CA, et al: Immunologic correlates of the abscopal effect in a patient with melanoma. N Eng J Med. 366:925–931. 2012. View Article : Google Scholar : PubMed/NCBI
45.	Keilholz U, Weber J, Finke JH, et al: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 25:97–138. 2002. View Article : Google Scholar : PubMed/NCBI
46.	Suzuki E, Sun J, Kapoor V, Jassar AS and Albelda SM: Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther. 6:880–885. 2007. View Article : Google Scholar : PubMed/NCBI